Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12851348 | 0.88 | TP53 (0.67) | KMT2ATP53SMN1; SMN2LMNAMAPT | |
| SCHEMBL10308345 | 0.83 | KMT2A (0.51) | KMT2AAKR1B1TP53RECQLSMN1; SMN2 | |
| SCHEMBL6112052 | 0.82 | KMT2A (0.47) | KMT2AAKR1B1TP53RECQLSMN1; SMN2 | |
| SCHEMBL13485815 | 0.82 | KMT2A (0.62) | KMT2AAKR1B1RECQLSMN1; SMN2ATM | |
| SCHEMBL9642442 | 0.81 | P2RX7 (0.50) | KMT2ATP53SMN1; SMN2MEN1LMNA | |
| SCHEMBL9527443 | 0.80 | KMT2A (0.61) | KMT2AAKR1B1RECQLSMN1; SMN2ATM | |
| SCHEMBL25144292 | 0.79 | HPGD (0.65) | KMT2AAKR1B1RECQLSMN1; SMN2MAPK1 | |
| SCHEMBL5001972 | 0.79 | KMT2A (0.51) | KMT2AAKR1B1RECQLSMN1; SMN2ATM | |
| SCHEMBL6393799 | 0.78 | NPC1 (0.56) | KMT2ASMN1; SMN2MEN1CYP3A4CYP2D6 | |
| SCHEMBL10646303 | 0.77 | KMT2A (0.57) | KMT2AAKR1B1RECQLSMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016950-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2010-05-06 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | RANBAXY LABORATORIES LIMITED INC. (IN) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075909-A1 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | KMT2A 4338/4885AKR1B1 343/4885TP53 3075/4885 |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KMT2A 1131/4885AKR1B1 1546/4885TP53 3384/4885 |
| US-20100113371-A9 | Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds | HLA-DRB1, IL5, TNF | KMT2A 4338/4885AKR1B1 343/4885TP53 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.